PRMT9 and osteosarcoma: Another research team found that PRMT9 was abnormally underexpressed in osteosarcoma and could inhibit glycolysis in osteosarcoma cells by increasing the instability of hypoxia inducible factor 1 α (HIF‐1 α) [7].